INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 43h ago
House PTR3h ago
SEC 13F3h ago
Robinhood Chain3h ago

Most active filers · 30d

  1. 01FWFogarty Patrick W0B / 206S206 trades$1.10M
  2. 02Kurtz George0B / 202S202 trades$48.06M
  3. 03SPSaba Capital Management, L.P.67B / 19S · 11 late86 trades$21.51M
  4. 04NYNissan Yitzhak82B / 0S · 79 late82 trades$2.61M
  5. 05ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  6. 06AJAllaire Jeremy0B / 50S50 trades$4.26M
  7. 07Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  8. 08SJSheena Jonathan0B / 45S45 trades$3.01M
  9. 09SISarowitz Steven I2B / 34S36 trades$21.18M
  10. 10SLSpeiser Michael L0B / 35S35 trades$14.00M

Cluster activity · 60d

  1. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  2. BUYMTDRMatador Resources CoNov 5 – Nov 189 insiders$1.02M
  3. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  4. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  5. SELLMGNIMAGNITE, INC.Nov 5 – Nov 178 insiders$2.77M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  8. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M

Form 4 transactions

73,431 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$13K
36 sh
Jan 12, 2026
Page 1501 of 1836
← PrevNext →
Jan 14, 2026
traded Jan 12, 2026
+2d
SEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$6,676
18 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$14K
39 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$7,137
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$387K
4,240 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$28K
76 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
NR
Neale Erin RoseSVP, Chief Legal Officer
SNCYSun Country Airlines Holdings, Inc.
Open-market sale
SELL$40K
2,257 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
SW
Simi Bonny WPresident of Operations
JOBYJoby Aviation, Inc.
Open-market sale
SELL$18K
1,232 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$27K
76 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$13K
34 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
MM
Mangione Christopher MichaelChief Acct. Off. & VP, Finance
SNCYSun Country Airlines Holdings, Inc.
Open-market sale
SELL$4,489
256 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
96 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
40 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$25K
72 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
BJ
Bevirt JoeBenDirector, CEO and Chief Architect, 10% Owner
JOBYJoby Aviation, Inc.
Open-market sale
SELL$24K
1,630 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$5,667
15 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$5,242
14 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
92 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
92 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$387K
4,240 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
92 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$18K
50 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
SM
Snow Colton MatthewSVP, Chief Commercial Officer
SNCYSun Country Airlines Holdings, Inc.
Open-market sale
SELL$13K
759 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$31K
85 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$9,361
25 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
40 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$1,117
3 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

35
AA
Armenta AnthonyChief Software & Data Officer
SERVServe Robotics Inc. /DE/
Open-market sale
SELL$56K
3,893 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

35
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$459K
1,259 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

35
FM
Frank MalcolmDirector
FDSFACTSET RESEARCH SYSTEMS INC
Open-market sale
SELL$308K
1,045 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

35
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$279K
778 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

35
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$353K
980 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

35
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$510K
1,395 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

33
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$156K
1,727 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

33
LF
Lo FrancisChief People Officer
ADPTAdaptive Biotechnologies Corp
Open-market sale · 10b5-1 plan
SELL$1.41M
79.6K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

33
SR
Soule Randy10% Owner
SAFXXCF Global, Inc.
Open-market sale
SELL$31K
200.0K sh
Jan 9, 2026Jan 14, 2026
traded Jan 9, 2026
+5dSEC Form 4

Evidence

33
SR
Soule Randy10% Owner
SAFXXCF Global, Inc.
Open-market sale
SELL$32K
200.0K sh
Jan 9, 2026Jan 14, 2026
traded Jan 9, 2026
+5dSEC Form 4

Evidence

33
SR
Soule Randy10% Owner
SAFXXCF Global, Inc.
Open-market sale
SELL$32K
200.0K sh
Jan 9, 2026Jan 14, 2026
traded Jan 9, 2026
+5dSEC Form 4

Evidence